When the Patient Becomes the Researcher
![Dr Sydney Stern sitting at her bench at University of Maryland Baltimore in 2021. Photo provided by: Sydney Stern](https://www.sarcoma-patients.org/wp-content/uploads/Dr-Sydney-Stern_cropped-791x1024.jpg)
Advocacy as a driving force for medical advancement
By DR. SYDNEY STERN, Biomedical Scientist and Patient Advocate.
An underdog disease
Much of my life was filled with mobility difficulties that were dismissed by my doctors as part of growing up. As a patient with a rare tumor disease, what I have been forced to learn about being a self-advocate is a result of hard, inescapable truths that this disease has limited options, if any, and specialists are as geographically disperse as patients are.
I was diagnosed at the age of 17 with a locally-aggressive, non-cancerous, sarcoma-like disease known as Tenosynovial Giant Cell Tumor (TGCT), previously called Pigmented Villonodular Synovitis (PVNS). During that time, I was studying medicine and physiology. Of particular interest was a pharmacology class which overlapped with my first surgery. During that class, I learned about many drug mechanisms, from chemotherapies for cancer to analgesics for chronic pain. Alongside my studies, like many patients and caretakers facing rare diseases and sarcoma, I found myself getting a ?Ph.D. and M.D. by Google and Pubmed? to understand what was happening.
The glaring name of the disease that was taking away my ability to walk was only conveyed through medical jargon in Magnetic Resonance Imaging (MRI), pathology, and post-operative reports. Those few letters, TGCT, changed the trajectory of my life, teaching me that through science, the unknown can become known.
At the time of my diagnosis, TGCT was characterized as a synovitis, an inflammation of the joint lining. Through science, advocacy, and advancement in medicine, the understanding of the disease and the paradigm of treatment transformed, so that TGCT fit into the realm of oncology and was treated by sarcoma specialists with targeted chemotherapies. This is due to the discovery of a molecular driver of the disease.
The collision of science and advocacy
Previously, advocacy and science had existed in two distinct silos, rarely coming into contact with each other. But something changed. While science pushed the boundary of the unknown and made things known, patient and physician advocates started demanding that something be done for this tiny group of oncology patients. Without the advocacy, the science would not have been translated into tangible treatment options.
This was the first instance I saw advocacy being the driving force, a requirement, for medical advancement. This experience of advocacy being the catalyst for improved treatments and patient care was again evident when SPAGN, TGCT Support, Life Raft Group, and I collaborated to create an expert consensus paper on TGCT and an accompanying patient-friendly version.
Through my engagement with the TGCT community, it became clear to me that patients bear the burden of the disease, the financial hardship, and the emotional and social toll; they were the single most motivated group to change their own outcomes and prognosis.
Educated patients are the greatest experts in the unique, lived experience of their disease, and can enhance research design and execution. They may not understand all of the nuanced vocabulary which acts as a barrier to patients being involved in their care, but they understand the impacts of the disease and can guide the formulation of research questions, so that they truly capture and quantify that experience.
Without patients acting as the pin cushion for medical progress, there would be no progress.
![](https://www.sarcoma-patients.org/wp-content/uploads/SPAGN22-TGCT-Consensus-Meeting_June22.jpg)
![](https://www.sarcoma-patients.org/wp-content/uploads/SPAGN22-TGCT-Consensus-Meeting_June22.jpg)
Patients and scientists at the TGCT consensus roundtable meeting in June 2022. Photo provided by: SPAGN.
Prioritizing the patient voice as part of the scientific method
That realization made me feel empowered: Patients can be part of the design, analysis, and interpretation of research from benchtop to bedside. I vowed to prioritize the patient voice as part of the scientific method, but not just as a box to be checked under the guise of ?patient engagement?. Sometimes this is easier said than done, but patients who have a seat at the table have contributed to the approval and discovery of many treatments. Their contributions are based on the acknowledgement that patients are capable of determining the level of risk they?re willing to incur given that the prospect of direct benefit exists, that they are provided with a reasonable amount of information, and that they have the ability to discuss it all with friends, family, doctors, and peers.
It's time for science to shake off the dusty old image of a laboratory in a dark basement with a mad scientist behind some beakers. Scientists must be engaged and invested in the community they serve, even those scientists who only work with tissue samples without ever meeting a patient.
How can patients get involved in research?
Here are 5 steps that you can take to play a role in the research of your own disease.
- Expand your health literacy, improving your ability to communicate and make decisions about your own health. This will strengthen your confidence to ask providers questions about your care and beyond, and even to discuss hypothesis-generating ideas, such as the symptoms that have the greatest quality of life impact and trends within the disease population. Patient involvement aids in the development of more targeted research that provides benefit to the community afflicted with the disease.
- Acknowledge the circumstances you are in and do the best given those circumstances. In my situation, as a scientist, the best I could do is science. While science may not be fast enough to change my situation, it is the best I could do. Whether you fill out surveys from advocacy organizations, go onto clinicaltrials.gov and participate in trials, or raise awareness with social media posts, do the best you can, within your capabilities. Sharing your lived experience facilitates collaboration and you?ll never know who will find you by sharing.
- Get involved in research through patient advocacy groups or organizations for your disease. There are many forms of collaborative efforts which allow patients to share their experience for researchers to gain insight into their experience. Patient advocacy groups cultivate the network and community of patients, caregivers, and clinicians which become prime opportunities for research. Ask advocacy organizations directly if there are opportunities to share experience and participate in research.
- Help develop educational programs for the community or your hospital. Through content created by patient advocacy groups and avid patient advocates, educational programs can be created within institutions and communities to promote awareness and drive research in your disease. For example, ask your treating physician if you can leave pamphlets for other patients or if there?s any opportunities to internally share your experience.
- Donate tissue samples after surgery. Institutions keep samples for long periods of time, and many offer you the opportunity to donate your samples to the physician/laboratory. This is especially common for academic cancer centers.
Patients are key to the development of research projects
Patient engagement and involvement in research can take many forms. The winning combination of raising awareness for the disease and promoting research is deeply reliant on patients sharing their experiences. You, as patients, are the key to the development of research projects and are a living embodiment of the impact treatment advances can have on your life, care, and future. Your story has power to change, motivate, and inform science and medicine.
Bio: Dr. Sydney Stern, Ph.D., M.S., a biomedical scientist and Director of TGCT Support, a program of the Life Raft Group. Its mission is to enhance treatment options and quality of life for patients with Tenosynovial Giant Cell Tumor (TGCT). Stern specializes in the discovery and development of treatments for rare diseases and cancers. She has authored numerous scientific publications, directed programs for cancer centers to improve bidirectional learning of early-stage clinicians/scientists and patients, served on multiple advisory boards for TGCT and patient advocacy groups, and is deeply involved in the rare disease and TGCT community.
Disclaimer: The opinions and views expressed in this blog are solely those of the author.
Dr Sydney Stern has been integral to bringing positive change to the landscape of TGCT.
Through her fierce desire to improve the patient journey she has helped people from all across the world?all while dealing with her own limitations with TGCT.
The dialogue in the support groups is noticeable changing from fear to courage due to her.
The strength that comes with greater knowledge and being about to share that with others is empowering.
The TGCT community will be forever in her debt.
When I was first diagnosed with TGCT I was deeply disappointed with the no treatment approach as my only option which in effect meant active surveillance. I just wanted the tumors removed and my life to go back to normal. But after speaking with Sydney, reading the patient friendly consensus paper, consulting TGCTsupport.org and making contact with the wider TGCT community, I now understand that I was blessed to not have been rushed into removal. From hearing about other people’s experiences in our support group and the knowledge I’ve built on, I have learned that removal isn’t always the best approach. My hope is that in the future, with the successful drug trials, treatment can be available to all who suffer across the globe at the hands of this rare disease.
The dedication of Sydney Stern to give the patient a voice and provide a constant source of support, information and empathy, has been integral in how we all see and choose to live with our disease, thank you so much for everything you do!
Thanks so much for sharing, Linda!
Sydney is the reason I found my doc and team. If not for her, I?d still be with a surgeon who didn?t know what to do w/ me. TGCT Support provides so much support for patients everywhere. I remember what it was like before the hope of treatment. I?m lucky everyday that I found the group and got on a drug instead of having my 10th surgery. Xxxx
Sarah, it’s wonderful to read how much TGCT Support has helped you! Thanks for your comment.
The support that the TGCT group has offered online is unbelievable. Living outside of the US in a small country the support I have is limited . However after having found Sydney and the TGCT group I know that I am not alone. I am forever indebted and grateful to this group and Sydney who are always there for support . I do not wish this disease upon anyone but feel optimistic for the future that everything possible is being done to eradicate it.
Shirin, thank you for your comment. So good that you found Sydney and the TGCT group — as a patient with a rare disease myself, I know that finding a great support group can really make all the difference!
When I was diagnosed with TGCT, the lack of comprehension of the source of the disease or reason for recurrence after surgery was apparent from my various doctors. So I decided to wait-and-see on my own over a decade ago and navigated life with pain from a compromised joint. Years later I decided to face the disease again, and the education and support I have received from our TGCT Support group and online community has been crucial to my decision making process. So much research and understanding has come to light from patients pushing for answers. Dr. Stern has dedicated herself to our cause and our collective experience. She consistently, thoughtfully and thoroughly shares the scientific data that we need to find clarity while acknowledging the emotionally challenging decisions that we as patients are forced to make in our disease journey. I am beyond grateful for her advocacy and dedication.
Thank you so much for telling us about the impact Dr Stern has had on your experience of your disease, Elizabeth!
I was lucky to find TGCT Support and Sydney before my first surgery. My doc had recommended RSO. My doctor was unaware of the consensus. Not only did Sydney intervene, send me the consensus paper, hook me up with a new doctor who was an author on it, but she checked in on me after my surgery and ultimately helped me get into a drug trial. Without the TGCT Support, I don?t know what would?ve happened to me. Now I get to be part of the research for a solution. I hate this disease but I?m proud to be in my community.
Thank you for writing about the invaluable help and support you got from Dr Stern, Kenneth!
Sydney is the gold standard in research, patient advocacy, and treatment. What she?s done for TGCT should be the model for all rare diseases, we need more scientists and providers to live and breathe this mindset. My initial diagnosis was at an academic center and I also would?ve had my tumors removed by an orthopedic surgeon who wasn?t knowledgeable about the disease, thankfully being my own advocate wasn?t new to me, so I knew I was going to have to find an expert who knew what this disease was and how to treat it. Thankfully, my search ended quickly when the first person I found was actually the expert of TGCT. When I saw that she is a patient and a scientist, I felt like I won the lottery. I wish every rare disease to find their Sydney Stern, her efforts make living with this relentless and miserable disease much more bearable.
Alexis, thank you for adding your voice to those of the others, and for letting us know how Dr Sydney has helped you (and the whole TGCT community).
I met Sydney through the support group. She?s changed so many lives. We are greatful for all her time and dedication to the community. Thank u for featuring her
[…] The mission of Dr Sydney Stern is to help improve quality of life through better research on the Tenosynovial giant cell tumour (TCGT) ? a rare, locally aggressive cancer that causes patients to experience pain, swelling and limited mobility. A patient herself in her younger years, Dr Stern became a researcher of TGCT and is determined to tackle the problem that there is still little evidence available. Since 2022, she and her collaborators from the TGCT program at the Life Raft Group have collected information from over 900 patients in 32 countries. Thus, they have created the largest worldwide database on TGCT patients covering demographics, diagnostic journeys, providers involved in diagnosis and care, management of disease and symptoms, monitoring of the disease and quality of life with the disease. With the help of this real-world information, so Sydney hopes, it will become easier to better identify the medical needs and provide multi-disciplinary and early treatments. Look for the forthcoming publication in a medical journal and a presentation at CTOS 2024! Also read her blog on her personal journey here. […]